KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Moderna (MRNA) Total Current Liabilities (2017 - 2026)

Moderna (MRNA) has disclosed Total Current Liabilities for 10 consecutive years, with $2.4 billion as the latest value for Q1 2026.

  • For Q1 2026, Total Current Liabilities rose 49.31% year-over-year to $2.4 billion; the TTM value through Mar 2026 reached $2.4 billion, up 49.31%, while the annual FY2025 figure was $2.0 billion, 9.93% down from the prior year.
  • Total Current Liabilities hit $2.4 billion in Q1 2026 for Moderna, up from $2.0 billion in the prior quarter.
  • Across five years, Total Current Liabilities topped out at $9.2 billion in Q1 2022 and bottomed at $1.6 billion in Q2 2025.
  • Average Total Current Liabilities over 5 years is $3.5 billion, with a median of $2.4 billion recorded in 2026.
  • Year-over-year, Total Current Liabilities plummeted 62.12% in 2023 and then skyrocketed 49.31% in 2026.
  • Moderna's Total Current Liabilities stood at $4.9 billion in 2022, then plummeted by 38.76% to $3.0 billion in 2023, then fell by 26.83% to $2.2 billion in 2024, then fell by 9.93% to $2.0 billion in 2025, then grew by 20.53% to $2.4 billion in 2026.
  • According to Business Quant data, Total Current Liabilities over the past three periods came in at $2.4 billion, $2.0 billion, and $1.7 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.